Drug intelligence / Profile preview

tetanus toxoid + diphtheria toxoid + inactivated poliovirus vaccine

Development stage
Phase 4
Lead developer
Parent
Modality
Vaccines & Immunotherapeutics
Administration
Intramuscular
01

Overview

**Tetanus toxoid + diphtheria toxoid + inactivated poliovirus vaccine** is a combination vaccine that induces active immunity against tetanus (caused by *Clostridium tetani* toxin), diphtheria (caused by *Corynebacterium diphtheriae* toxin), and poliomyelitis (caused by poliovirus types 1, 2, and 3). It contains detoxified tetanus and diphtheria toxoids to stimulate antibody production neutralizing the respective toxins, alongside inactivated poliovirus antigens for humoral and mucosal immunity against polio. Primarily used as a booster in adolescents and adults for maintaining protection, especially in regions like the UK where it is administered around age 14; toxoids are adsorbed onto aluminum adjuvant for enhanced immunogenicity, with no pertussis component distinguishing it from DTaP-IPV vaccines.

Brand names
DT-IPV
Other names
DT + IPVTd/IPV
02

Targets

Diphtheria toxinPRR (Pattern recognition receptors)

Beyond the preview

Go deeper on tetanus toxoid + diphtheria toxoid + inactivated poliovirus vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on tetanus toxoid + diphtheria toxoid + inactivated poliovirus vaccine.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call